Usefulness of NT-Pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity

Journal of Clinical Psychopharmacology

Volumn 31, Issue 6, 2011, Pages 712-716

  Rostagno, Carlo ^a   Domenichetti, Sandro ^b   Pastorelli, Francesca ^a   Gensini, Gian Franco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Servizio di Psichiatria ASL 10   (Italy)

Author keywords

cardiotoxicity; clozapine; echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CLOZAPINE;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; LONG TERM CARE; MALE; MEASUREMENT; MENTAL PATIENT; ORGANIC BRAIN SYNDROME; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PSYCHOPHARMACOTHERAPY; QT INTERVAL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CLOZAPINE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80755175892     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318234ee66     Document Type: Article

References (27)

1. Tihonen J, Lonnqvist J, Wahlbeck M, et al. 11-year follow-up of mortality in patients with schizophrenia : a population based cohort study (FIN 11 study). Lancet. 2009;374:620-627.
2. Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapiramidal side effects. BMJ. 2000;321: 1360-1361.
3. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
4. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91. (Pubitemid 36070868)
5. Güzelcan Y, Scholte WF. Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model. Tijdschr Psychiatr. 2006;48:295-302.
6. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
7. Jensen VE, Gotzsche O. Allergic myocarditis in clozapine treatment. Ugeskrift for Laeger. 1994;156:4151-4152.
8. Merril DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25:32-41. (Pubitemid 40129380)
9. Reinders J, Parsonage W, Lange D, et al. Clozapine related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Austr NZ Psychiatry. 2004;38:915-922. (Pubitemid 40028895)
10. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007;30:47-57. (Pubitemid 46072357)
11. Kelly DL, Mc Mahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304-311.
12. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
13. Lang RM, Beng N, Devereux RB, et al. Recommendations for chamber quantification : a report from the American Society of Echocardiography's guidelines and standard committee and the chamber quantification working group, developed in conjunction with the European Society of Echocardiography, a branch of European Society of Cardiology. Am J Echocardiogr. 2005;18:1140-1463.
14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108. (Pubitemid 43257193)
15. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine in the United States. N Engl J Med. 2001;345:224-225. (Pubitemid 32662140)
16. Wehemeier PM, Heiser P, Remschmidt H. Myocarditis and cardiomyopathy in patients treated with clozapine. J Clin Pharmacol Ther. 2005;30:91-96. (Pubitemid 41602097)
17. Leo RJ, Kreger JL, Kim KY. Cardiomyopathy associated with clozapine. An Pharmacother. 1996;30:603-605. (Pubitemid 26181700)
18. Akem E, Strauge P. Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol. 2004;67:2039-2045.
19. Wang JF, Min JY, Hampton TG, et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol. 2008;592:123-127.
20. Cohen H, Loeventhal U, Mutar M, et al. Association of autonomic dysfunction and clozapine heart rate variability and risk of sudden death in patients with schizophrenia on long-term psychotropic medications. Br J Pharmacol. 2001;179:167-171. (Pubitemid 32756500)
21. Kim SYJ, Kim KT, Choe H, et al. Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol. 2006;148:499-550.
22. Fenelon G, Wijns W, Andries E, et al. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol. 1996;19:95-106. (Pubitemid 26033209)
23. Walker NL, Cobbe SM, Birnie DH. Tachycardiomyopathy: a diagnosis not to be missed. Heart. 2004;90:e7.
24. Rostagno C, Di Norscia G, Placidi GF, et al. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry. 2008;30:280-283. (Pubitemid 351538957)
25. Williams DP, O'Donnell CJ, Maggs JL, et al. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem Res Toxicol. 2003;16:1359-1364. (Pubitemid 37315224)
26. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. (Pubitemid 40677047)
27. Floreani J, Bastiampillai T. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry. 2008;42:747-748.